E ndothelial cells (ECs) form the internal barrier of vasculature and play fundamental roles in vascular development and diseases. Most blood vessels remain quiescent and function to conduct nutritive blood flow; however, they can resume an active proliferation program governed by a complex milieu of growth factors and signaling networks to generate new blood vessels in a process broadly termed angiogenesis.
to pathological angiogenesis; indeed an antibody against vascular endothelial growth factor (Vegf) was approved for therapy in metastatic cancers and macular degeneration. 1, 2 However, resistance to Vegf blockade develops because of upregulation of other angiogenic growth factors, and inhibition of multiple pathways provides synergy and is more effective than targeting a single growth factor-dependent pathway. 3 Thus, a better understanding of major regulators of angiogenesis may ultimately lead to the development of more effective antiangiogenic therapies.
MicroRNAs (miRNAs) are small noncoding RNAs that regulate RNA translation and stability at a post-transcriptional level and participate in a diverse range of regulation of genes involved in the control of development, differentiation, homeostasis, metabolism, growth, proliferation, and apoptosis. 4 A powerful indication for indispensable roles of miRNAs in angiogenesis was shown by EC or vascular smooth muscle cell-specific deletion of Dicer, an enzyme essential for miR-NA biogenesis, resulting in defective blood vessel development and EC function. 5, 6 The function of individual miRNAs in angiogenesis is beginning to be elucidated, and miRNAs can represent a future therapeutic target for the treatment of pathological neovascularization-related diseases because of their target of multiple pathways. 7 The miR302-367 cluster is located in intron 8 of Larp7 gene. It is highly expressed in embryonic stem cells 8 and plays a crucial role in embryonic stem cell self-renewal and somatic cell reprogramming. 9, 10 MiR302-367 cluster has 5 members: miR302a, miR302b, miR302c, miR302d, and miR367. Our previous publication demonstrated that the miR302-367 cluster directed lung endoderm development, driving a profound increase in cardiomyocyte proliferation to promote mammalian cardiac repair and regeneration. 11, 12 Recent studies reported that miR302 inhibited tumorigenicity through suppression of cell cycle progression, Akt signaling, endothelial-mesenchymal transition pathway, and so on, [13] [14] [15] but its roles in angiogenesis and neovascularization-related diseases have not yet been elucidated. Here, based on genetic and pharmacological experiments in mouse and ex vivo and in vitro studies, we report that miR302-367 inhibits angiogenic sprouting and promotes vascular stability in an EC autonomous manner. These functions are mediated via suppression of Erk1/2 expression by miR302-367, which increases expression of Krüppel-like factor 2 (Klf2), and in turn sphingosine1-phosphate receptor 1 (S1pr1) and vascular E-cadherin (VE-cadherin). We propose that miR302-367 provides an endogenous and essential protection against angiogenic sprouting and hyperpermeability in both development and tumor vasculature and potently retards tumor growth.
Methods

Generation of Vascular EC-Specific Elevated MiR302-367 Expression Mice
The gain-of-function R26R-miR302-367
Tg/+ mice 12 were crossed with VE-cadherin (Cdh5) 16 or smooth muscle myosin heavy chain (SmMHC) promoter-driven Cre 17 to generate cell-specific elevated miR302-367 expression mice R26R-miR302-367 Tg Figure  IB ) and reporter mice R26R-tdTomato-EGFP:miR302-367 ECTg (Online Figure IC) were obtained by similar approach. The procedures performed on mice were in accordance with the Institutional Animal Care and Use of Laboratory Animals was approved by the Tongji University Institutional Animal Care and Use Committee.
Study of Angiogenesis
We used a well-established mouse retinal angiogenesis in vivo model. 18 Detailed protocols, gain of function by miR302-367 mimic, loss of function by inhibiting miR302-367 with anti-miRs on retinal angiogenesis, ex vivo and in vitro angiogenic assays, and EC high-throughput RNA sequence were described in Online Materials and Methods.
Xenograft Tumor Model and Tumor Angiogenesis
Lewis lung carcinoma cell and B16 cell xenograft tumor angiogenesis and tumor growth were investigated in miR302-367
ECTg mutant and littermate control mice. Detailed protocols and statistical analysis were described in Online Materials and Methods.
Statistical Analysis
Data were presented as mean±SEM of at least 3 independent assays unless otherwise noted. Student t test was used for single comparisons and 1-way ANOVA analysis for multiple comparisons. P<0.05 was considered significant and P<0.01 very significant.
Results
MiR302-367 Cluster Expression in ECs and Reduced Expression When Cocultured With LLC1 Cells
Recent studies reported that downregulation of miR302 expression in various types of tumor tissues 13, 14 increased expression of miR302-suppressed tumor growth [13] [14] [15] and inhibited tumorigenicity of human pluripotent stem cells. 19 However, it is not clear in which cell type miR302-367 exerts its regulation of tumor growth. Our study confirmed downregulation of miR302-367 in LLC1 xenograft tumor compared with normal lung tissue ( Figure 1A) , and a significant downregulation of miR302-367 in human umbilical vein endothelial cells (HUVECs) was observed when cocultivated with LLC1 ( Figure 1B ), but not in LLC1 cells ( Figure 1C ). MiR302-367 cluster has 5 members (miR302a, miR302b, miR302c, miR302d, and miR367), and our further investigation showed that miR302-367 expression in ECs during embryonic development and found that all 5 members expressed at embryonic stage with greatest at E9.5, E11.5, decreased after E15.5 with low expression level at postnatal ECs ( Figure  1D ). These data suggested that miR302-367 expressed in ECs and might be involved in regulation of angiogenesis. 
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Elevated miR302-367 Expression in HUVECs Impairs Angiogenic Sprouting and Migration
To test whether miR302-367 expression in ECs regulates angiogenic processes, we generated lentivirus-carrying miR302-367 cluster. Successful lentiviral delivery into HUVECs was confirmed by fluorescent microscopy with ≥90% infection efficiency in HUVECs (Online Figure IIIA) . All members of miR302-367 cluster were significantly increased in HUVECs after lentivirus-miR302-367 infection for 48 hours compared with the control lentiviral-eGFP (Online Figure IIIB) . Reduced formation of sprouts led by tip cells and reduced number of scattered cells in fibrin gel bead-based sprouting assay were observed in HUVECs infected with lentivirusmiR302-367 compared with HUVECs infected with the control lentiviral-eGFP (Figure 2A and 2B) . Similarly, marked attenuation of tube formation was observed in HUVECs with elevated miR302-367 expression, with reduction of branch points and total tube length (Online Figure IIIC and IIID) . Taken together, in vitro angiogenesis demonstrated the reduction of angiogenic activity on elevation of miR302-367 expression in ECs. Migration of ECs is important for sprout angiogenesis. Both scratch wound-healing assay ( Figure 2C and 2D) and Boyden chamber assay ( Figure 2E and 2F) confirmed the reduction of cell migration in HUVECs with elevated expression of miR302-367, but no significant change of cleaved caspase-3 expression was observed (Online Figure IIIE) . These results suggested that the reduction of in vitro angiogenesis on elevated miR302-367 expression might be because of inhibition of cell sprout and migration but not cell apoptosis.
Elevated EC expression of miR302-367 cluster reduces developmental angiogenesis in vivo and ex vivo and improves vascular stability.
To confirm whether reduction of in vitro angiogenic activity on elevation of miR302-367 expression in HUVECs can be replicated in vivo, we generated miR302-367
ECTg or miR302-367 SMCTg mice (Online Figure IA) . Increased expression of all 5 members of miR302-367 cluster was confirmed by quantitative polymerase chain reaction (qPCR) in lungs Figure IVC) Figure  3A . miR302-367
ECTg mutant mice exhibited a marked reduction of retinal vessel outgrowth length ( Figure 3B and 3E), branching points ( Figure 3B and 3F), sprout filopodia ( Figure 3B and 3G) and vessel area in retina ( Figure 3B and 3H) and a significant reduction of EC Ki67 staining, a cell proliferation marker (Online Figure IVD) compared with control littermates. Next, we performed cardiac perfusion of 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate to demonstrate blood vessel perfusion of retina. 20 As expected, impaired angiogenesis resulted in less blood perfusion area in retina of miR302-367
ECTg mutant mice (Online Figure VA and VB). Furthermore, the miR302-367
ECTg mutant mice exhibited significant anti-angiogenic activity on embryonic hindbrain ( Figure 3C , 3D and 3I) and a significant reduction of angiogenic sprouting of aortic ring explants ex vivo ( Figure 3J and 3K). In contrast, miR302-367 SMCTg mice exhibited no significant change of retinal vessel branching points and sprout filopodia (Online Figure VIA through VIC). These data indicated that elevation of miR302-367 specifically in ECs reduced developmental angiogenesis in vivo and angiogenic sprouting ex vivo.
Angiogenic sprouting leads to expansion of new vessels, which are immature and hyperpermeable, and subsequent vascular remodeling generates mature and stable vessels without permeability. Retinal vasculature between 5 and 8 postnatal days (P) can be used to study the vessel stability, 21 and we used modified miles assay to quantify vascular permeability of miR302-367 ECTg mice at P6. Reduction of Evans blue dye leakage in lung microvessels of miR302-367
ECTg mice was observed compared with the control wild-type mice ( Figure 3L ), which was further confirmed by the Evans blue dye absorption of lung ( Figure 3M ) and retina ( Figure 3N ). These results demonstrated that elevated expression of miR302-367 in ECs not only restricted angiogenetic sprouting but also improved vascular stability during retina vasculature development.
Individual Member of MiR302-367 Cluster Exerts Antiangiogenic Effect In Vivo and In Vitro
We next performed experiments to investigate the effect of individual member of miR302-367 cluster on retinal angiogenesis in vivo and HUVEC sprout angiogenesis in vitro. Individual miR302a/b/c/d mimic, miR367 mimic, and mimic mixture were used; elevated miR302-367 expression of individual members in retina was confirmed by qPCR (Online Figure VIIA) . Individual miR302a/b/c/d and miR367 mimic and mixture mimics had similar retinal antiangiogenic effects with significant reduction of retinal vessel outgrowth length ( Figure 4A through 4C) and branching points ( Figure 4A , 4B, and 4D) similar to miR302-367 ECTg mice. The most robust effect was observed when miR302-367 cluster was inhibited with mimic mixture, whereas individual miR302a/b/c/d mimic had the similar but less profound effect, and miR367 had least effect. Our further in vitro beads sprout angiogenesis of HUVEC showed that miR302-367 expression was elevated by individual miR302-367 mimic (online Figure VIIB) and the similar anti-angiogenic effect was observed in individual miR302-367 mimic and their mixture ( Figure 4E through 4H) , confirming the role of miR302-367 cluster as well as its members in angiogenesis.
Loss-of-function studies on sprout angiogenesis in P5 retina by inhibiting miR302-367 with anti-miRs were investigated, and significant reduction of miR302-367 was observed when anti-miRs for inhibition of miR302-367 were used (Online Figure VIIC) . When miR302-367 cluster was reduced by anti-miRs, we observed that outgrowth length angiogenic branch points, filopodia sprouts, and vessel area in retina were significantly increased ( Figure 4I through 4N ). This phenotype of increased angiogenesis in miR302-367 anti-miR-treated mice was consistent with our gain-of-function findings that miR302-367 inhibited angiogenesis in retina and embryonic hindbrain of miR302-367
ECTg mice ( Figure 3A through 3I). Thus, our results confirmed that EC mir302-367 negatively regulated angiogenesis.
Elevated EC Expression of miR302-367 in Mice Reduces Tumor Angiogenesis, Improves Vascular Stability, and Retards Tumor Growth
Because tumor angiogenesis shares features of many development angiogenesis pathways, we next studied whether elevated miR302-367 expression in ECs affected tumor angiogenesis, and whether these changed angiogenesis had effects on tumor growth. To address these questions, 2 xenograft tumor growth models (LLC1 and B16) were used in miR302-367
ECTg and control littermates. The schematic chart of tamoxifen administration for induction of elevated expression of miR302-367 in ECs to analyze angiogenesis in xenograft tumor was shown in Online Figure VIIIA. Increased expression of miR302-367 was confirmed in LLC1 and B16 xenograft tumor of miR302-367
ECTg recipient mice (Online Fig. VIIIB and VIIIC) . Indeed, a significantly reduced final tumor size ( Figure 5A ) and tumor mass ( Figure 5B), and a significant reduction of blood vessel density in LLC1 xenograft tumor ( Figure 5C and 5D) were observed in miR302-367
ECTg mice compared with littermate control mice. Similar antiangiogenic and tumor inhibitory effect were obtained in another B16 xenograft tumor model ( Figure 5E and 5H) .
Furthermore, we performed 3-dimensional intravital microscopy observation of in vivo blood vessels and confirmed a significant reduction of the vessel branch points within xenograft tumor of host tdTomato-EGFP:miR302-367 ECTg mice ( Figure 5I and 5J). Significant reduction of Evans blue dye leakage was also found in xenograft tumor of miR302-367 ECTg mice ( Figure 5K and 5L). These data suggested that ECspecific elevated expression of miR302-367 restricted sprout angiogenesis and improved vessel stability of tumor and hence retarded the tumor growth.
Next, we observed whether reduced tumor size was because of hypoxia or impaired proliferation of tumor cells.
Ki67, Glut-1, and CA-9 were stained in tumor sections. Our results showed that miR302-367
ECTg mice exhibited significantly increased Ki67 staining in tumor cells, but no change of Glut-1 and CA9 (Online Figure VIIID through VIIIF) , which indicated that impaired proliferation of tumor cells, not hypoxia, leads to smaller final tumor size in miR302-367 ECTg mice. Taken together, elevated EC expression of miR302-367 restricts tumor angiogenesis, leading to impaired tumor cell proliferation, which in turn results in suppressing tumor growth.
Erk1/2 Are Identified as Direct Targets of MiR302-367 in ECs
To identify the target genes of miR302-367 contributing to restriction of sprout angiogenesis, we performed RNA highthroughput sequence of lung ECs from miR302-367
ECTg and the littermate controls. The results showed no significant change of Vegf and Akt but marked reduction of Erk1/2 expression in miR302-367 ECTg mice, which was confirmed by qPCR ( Figure 6A ) and Western blot ( Figure 6B ) with quantification (Online Figure IXA through IXC) . ECTg mouse embryos. J and K, miR302-367 ECTg mice exhibit reduced angiogenic sprouts of aortic ring explants. Significant reduction of aortic sprouts is shown at low magnification (J, left) and at high magnification (J, right) with reduced branch point indicated by the red dots (J). L and N, miR302-367 ECTg mice exhibit reduced permeability of lung vasculature with decreased Evans blue dye (EBD) extravasation in lung (L and M) and P6 retina (N). *P<0.05; **P<0.01; ***P<0.001. Scale bars: B=2 mm (top), =100 µm (middle), and =10 µm (bottom); D=50 µm; J=200 µm (left) and =30 µm (right); L=5 mm. Through analyzing multiple databases, including Target Scan, MiRanda, and PicTar, we confirmed Erk1/2 as possible target of miR302-367. MicroRNAs bind with 3′ untranslated region (3′-UTR) to direct gene post-transcriptional repression. 22 Sequence analysis showed miR302-367-binding sites in 3′-UTR of Erk1 or Erk2 ( Figure 6D ). Expression of miR302-367 suppressed the luciferase activity of 3′-UTR reporter, and mutation of the seed sequences of miR302-367-binding site restored the luciferase activity ( Figure 6E ). Further individual miR302a/b/c/d mimic, miR367 mimic, and mimic mixture were used in 3′-UTR luciferase assay, and we indeed found that the mimics and mimic mixture can repress 3′-UTR of Erk1/2 as miR302-367 cluster vector did ( Figure 6F ). These data suggested that Erk1/2 might be the direct target of miR302-367, and downregulation of Erk1/2 on elevated expression of miR302-367 might contribute to restricted angiogenesis.
Reduced Erk1/2 on Elevated Expression of miR302-367 Increases Klf2, S1pr1, and VE-Cadherin Expression in ECs
Apart from reduced Erk1/2 expression, RNA sequence analysis showed remarkably increased Klf2 expression in ECs on elevated expression of miR302-367, which was confirmed by qPCR ( Figure 6A ) and Western blot ( Figure 6B ). It was reported that in mouse embryonic stem cells, Erk2 phosphorylated and proteosomally degraded Klf2, thus reduced Erk2, increased Klf2 expression, and increased Klf2 RNA level. 23 We then looked at whether Erk1/2 regulated Klf2 expression in ECs. Co-immunoprecipitation assays were performed in HUVECs, and the result showed that Erk1/2 could pull down Klf2 (Figure 6C ), confirming the association between Erk1/2 and Klf2 in ECs. We then found that activation of Erk1/2 by Vegf suppressed the enhanced Klf2 expression in HUVECs on elevated expression of miR302-367, and this effect was reversed by an Erk1/2 selective inhibitor SCH772984 ( Figure 6G ), further confirming that reduced Erk1/2 on miR302/367 elevation in ECs would increase Klf2 expression.
Klf2 was reported to be a crucial transcription factor to enhance S1pr1 expression in T cells. 24 We then investigated whether elevation of Klf2 in ECs increased S1pr1 expression. As expected, ≈3-fold increased Klf2 expression in HUVECs after transfection of pBRPyCAG-hKlf2-DsRed-Ip (a gift from Rudolf Jaenisch; Addgene; plasmid no. 26277) 25 enhanced S1PR1 expression ( Figure 6H and 6I), explaining the RNA sequence results that S1pr1 expression were increased in lung ECs of miR302-367 ECTg mice. Because S1pr1 signaling positively regulated VE-cadherin and, therefore, enhanced EC-to-cell adhesion, 26 we further investigated whether miR302-367 could influence the expression of VE-cadherin in ECs via S1pr1 signaling. Our data showed that total VE-cadherin expression is upregulated in ECs of miR302-367
ECTg mice ( Figure 6A and 6B), and junctional VE-cadherin were enhanced in HUVECs 
exhibit reduced growth of Lewis lung carcinoma (LLC1) xenograft tumor (A and B), with reduction of host vessel density (C and D). E-H, miR302-367
ECTg mice exhibit reduced growth of B16 xenograft tumor (E and F), with reduction of host vessel density (G and H). I and J, Intravital visualization of blood vessels within the xenograft tumors by 2-photon microscopy shows reduced branch numbers of vessels in miR302-367 ECTg mice. K and L, miR302-367 ECTg mice exhibit reduced Evans blue dye extravasation in LLC1 xenograft tumor. **P<0.01. Scale bars: A and E=10 mm; C and G=100 µm; I=40 µm; K=5 mm.
infected with lentivirus-miR302-367, whereas blockade of S1PR1 weakened the enhanced junctional VE-cadherin (Online Figure XA) .
Together, these data supported the hypothesis that elevation of miR302-367 in ECs inhibited Erk1/2, which led to the increased expression of Klf2 and in turn S1pr1 and Figure 6 . miR302-367 cluster, as well as individual members, directly targets Erk1/2 and negatively regulates the expression of Klf2, S1PR1, and VE-cadherin in endothelial cells (ECs). A and B, miR302-367 ECTg mice exhibit decreased expression of Erk1/2, increased expression of Klf2, S1pr1, and VE-cadherin expression in lung ECs as determined by quantitative polymerase chain reaction (qPCR; A) and Western blotting (B). C, Co-immunoprecipitation assay shows that Erk1/2 pulls down Klf2 in human umbilical vein endothelial cells (HUVECs). D, miR302-367 sequence matches 3′-untranslated region (UTR) sequence of Erk1 and Erk2. E, miR302-367 cluster represses the luciferase activity of 3′-UTR of Erk1 (the upper bar graph) or Erk2 (the lower bar graph), and mutation of the binding site abolishes the luciferase repression. F, Individual miR302a/b/c/d mimic, miR367 mimic, miR302-367 mimic mixture, and miR302-367 cluster vector all represses the luciferase activity of 3′-UTR of Erk1 (the left bar graph) or Erk2 (the right bar graph), and mutation of the binding site abolishes the luciferase repression. G, Elevated miR302-367 expression in ECs reduces the levels of phospho-and total Erk1/2 protein and increases the expression of Klf2, S1PR1, and VE-cadherin protein, and the expression level changes of Erk1/2, Klf2, S1PR1, and VE-cadherin are reversed by activation of Erk1/2 by Vegf (30 ng/µL); however, this reversion is abolished by an Erk1/2 inhibitor SCH772984 (20 µmol/L). H and I, Klf2 overexpression in HUVECs through plasmid-mediated gene transfer enhances S1PR1 expression at protein (H) and mRNA (I) level. n.s. indicates not significant; *P<0.05; **P<0.01.
VE-cadherin, resulting in restriction of sprout angiogenesis and improvement of vessel stability.
S1pr1 Mediates the Downstream Signaling of miR302-367 Cluster to Restrict Angiogenesis and Improve Vessel Stability
S1pr1 is the main receptor in ECs. It was reported that S1pr1 and its downstream target VE-cadherin restricted sprouting angiogenesis and improve vascular stability. 27 To determine whether upregulation of S1pr1 is responsible for the reduction of retina sprout angiogenesis and improvement of vascular stability on elevated miR302-367 expression, a selective S1pr1 antagonist W146 and genetic S1pr1 deficient S1pr1 fl/fl :miR302-367 ECTg mice were used (Online Figure IB) . The results showed that pharmacological blockade of S1pr1 with W146 treatment in miR302-367
ECTg mice was able to reverse the reduction of retina angiogenesis ( Figure 7A ) with significant increase of vessel outgrowth length ( Figure 7B ), vessel branching points ( Figure 7C ), and sprout filopodia ( Figure 7D ) compared with control vehicle in miR302-367
ECTg mice. The reduction of retina angiogenesis in miR302-367 ECTg mice was reversed by genetic deletion of endothelial S1pr1 in S1pr1 fl/fl :miR302-367 ECTg mice as well ( Figure 7A through 7D) . Moreover, pharmacological blockade of S1pr1 in miR302-367 ECTg mice or genetic deletion of S1pr1 reversed the upregulation of total and junctional VE-cadherin, resulting in mislocalization of VE-cadherin ( Figure 7E ), and therefore reversed the reduction of vascular permeability ( Figure 7F through 7H) observed in miR302-367 ECTg mice. In agreement with the in vivo results, further study of ex vivo angiogenic sprouting of aortic ring explants showed that W146 treatment was able to reverse the miR302-367-mediated reduction of cell sprouting (Online Figure XB and D) , and the same results were noted in in vitro fibrin gel bead sprout assay (Online Figure XC and XE) .
Together, these data showed that EC-specific expression of miR302-367 increased S1pr1 expression and its downstream VE-cadherin expression, which restricted angiogenic sprouting in vivo, ex vivo, and in vitro, and improved vascular stabilization in angiogenic development in retina in vivo. This effect could be reversed by both pharmacological blockade of S1pr1 and genetic deletion of S1pr1 in ECs.
EC-Specific Elevated MiR302-367 Expression in Both Genetic Model and RGD-Peptide Magnetic Nanoparticle-Delivered MiR302-367 Mimics Impairs Tumor Growth by Restricting Tumor Angiogenesis and Improving Vascular Stability via S1pr1-Dependent Pathway
To investigate whether EC-specific elevation of miR302-367 expression inhibits tumor growth via the same pathway as observed in development angiogenesis, we measured the expression level of Erk1/2, Klf2, S1pr1, and VEcadherin in LLC1 xenograft tumor of miR302-367 ECTg mice and confirmed the reduced expression of Erk1/2 (Online Figure XIA) , but increased expression of Klf2, S1pr1, and VE-cadherin (Cdh5; Online Figure XIB ) compared with littermate control mice. Systemic infusion of W146, the S1pr1 selective inhibitor, reversed the reduction of tumor size and weight in miR302-367
ECTg recipient mice ( Figure 8A and 8B) . We further applied intravital 2-photon microscopy to visualize tumor vasculature in vivo and found that elevated expression of miR302-367 in host ECs significantly reduced tumor angiogenesis, and this phenotype was reversed by treatment of W146 (Figure 8D and 8E ; Online Movie I). This suggested that S1pr1-mediated restriction of angiogenesis impaired tumor growth on elevated miR302-367 expression in ECs.
Next, we tested whether EC-specific elevation of miR302-367 reduced tumor vascular permeability via S1pr1-dependent pathway. Evans blue dye leakage was less prominent in tumor of miR302-367
ECTg mice compared with the wild-type control mice, and this reduced vascular permeability was reversed by W146 treatment (Figure 8A and 8C). Furthermore, we intravenously infused fluoresbrite-labeled microspheres to observe extravasation of microspheres by 2-photon microscopy, the in vivo assay for host tumor vasculature permeability. The results showed that microspheres were detected in xenograft tumor stroma surrounding blood vessels of wild-type mice; however, no extravasation of microsphere was observed in miR302-367 ECTg mice, but more microspheres were observed in the stroma of miR302-367
ECTg mice when treated with W146 (Online Figure XIA and XIB) . There was similar smooth muscle cell coverage of retinal vessels (Online Figure XIIC) and blood vessels in xenograft tumor (Online Figure XID) between miR302-367 ECTg and control littermates, indicating that decreased vascular permeability might result from enhanced endothelial junction adhesion in miR302-367 ECTg mice and not because of smooth muscle cell coverage of blood vessels.
Furthermore, we constructed an RGD (Arg-Gly-Asp) peptide-containing magnetic nanoparticle to achieve controlled and target delivery of miR302-367 mimic to EC specifically, and tumor angiogenesis and tumor growth were examined. The results indicated that more RGD peptide magnetic nanoparticles entered into ECs compared with non-RGD-peptide nanoparticles. The control nanoparticles without miR302-367 showed no effects on tumor angiogenesis and growth compared with that of PBS treatment (Online Figure XIII) . These data demonstrated that RGDpeptide nanoparticles could be delivered to tumor ECs more efficiently without significant change of tumor angiogenesis and growth.
RGD peptide magnetic nanoparticles packed with individual miR302b/c, miR367 mimic, or mimic mixture were given by tail vein injection ( Figure 8G) , and elevated expression of individual members of miR302-367 in ECs of tumor was confirmed by qPCR (Online Figure XIV) . Individual miR302b/c and miR367 mimic and the mimic mixture for whole miR302-367 cluster were found to reduce blood vessel density of tumor and final tumor size, similar to what we observed in miR302-367 ECTg mice. The most robust effect was observed in the mimic mixture followed by individual miR302b/c mimic and the least effect in mice treated with miR367 mimic (Figure 8G through 8L). These data demonstrated that individual miR30-367 mimic delivered by RGD peptide magnetic nanoparticles had the similar antiangiogenic effects and impaired the tumor growth as that observed in miR302-367 ECTg mice. Together, these results suggested that EC-specific elevated miR302-367 expression in both genetic mouse model and RGD peptide magnetic nanoparticle-delivered miR302-367 mimics retarded tumor growth via reducing host angiogenesis and improving vascular stability through the same S1pr1-VE-cadherin-dependent pathway as development retinal angiogenesis.
Discussion
We presented here the evidences that Erk1/2 was direct target of miR302-367, and reduced expression of Erk1/2 upregulated Klf2 and S1pr1. The increase of S1P-signaling pathway resulted in upregulation of VE-cadherin in EC junction, therefore restricted angiogenesis and improved vascular stability.
Elevated expression of miR302-367 in different cell types might produce divergent changes. Our previous studies demonstrated increased cell proliferation of lung epithelial cells and cardiomyocytes on elevated miR302-367. In ECs, ECTg mice, which are reversed by inhibition of S1pr1 by W146 or genetic deletion of EC S1pr1. E, VE-cadherin staining displays endothelial junctions in a diffuse and uniform pattern of retina in wild-type mice, increased VE-cadherin staining with less junction gap of miR302-367 ECTg mice, but decreased and irregular VE-cadherin staining with heterogenous in intensity and more distinct junction (red arrow heads) of miR302-367 ECTg mice treated with W146 or genetic deletion of EC S1pr1. F-H, miR302-367 ECTg exhibit reduction of Evans blue dye (EBD) extravasation, in lungs (F) with quantification in lung (G) or P6 retina (H), which is reversed by S1pr1 inhibitor W146. *P<0.05; **P<0.01; ***P<0.001. Scale bars: A=2 mm (top), 100 µm (middle), and 10 µm (bottom); E=50 µm; F=5 mm.
it exerted antiangiogenic effect. Gain of function of mir302-367 in ECs strongly retarded angiogenesis both in vivo and in vitro, whereas loss of function of mir302-367 cluster enhanced angiogenesis. We further found that individual miR302a/b/c/d and miR367 mimic, as well as miR302-367 cluster, all displayed the similar antiangiogenic effect, with most robust effect in miR302-367 cluster but less profound effect in individual miR302a/b/c/d and the least in miR367 mimic treated mice.
Tumor angiogenesis shares many features of developmental angiogenesis, and it is important for tumor growth. Downregulation of miR302-367 cluster has been reported recently in various types of tumors, 13, 14 and its elevated expression can inhibit tumorigenicity and tumor growth. ECTg mice. This phenotype is reversed by S1pr1 inhibitor W146. D and E, miR302-367 ECTg mice exhibit reduced vessel branch points in xenograft tumor in vivo by 2-photon microscopy. The green color represents host mice-derived blood vessels, which is significantly reduced in tdTomato-EGFP:miR302-367 ECTg mice and reversed by W146. G, The schematic chart of RGD peptide nanoparticle delivered miR302-367 mimics to tumor vascular endothelial cells for the analysis of tumor growth. H-L, RGD peptide nanoparticles packed with miR302-367 mimic significantly reduce the tumor size (H-I and K) and vessel density in tumor (J and L). Data quantification is mean±SEM. (n=6). n.s. indicates not significant;*P<0.05; **P<0.01. Scale bars: A=5 mm; D=40 µm; K=5 mm; L=50 µm.
We showed that miR302-367 was reduced in LLC1 xenograft tumor and downregulated in HUVECs when cocultured with LLC1, not in LLC1 tumor cell itself; therefore, we investigated function of EC miR302-367 in xenograft tumor model and demonstrated that EC elevated expression of miR302-367 cluster by genetic approach or RGD peptide nanoparticles packed with miR302-367 mimic all reduced the vascular density of xenograft tumor, leading to impaired proliferation of tumor cells and therefore retarded tumor growth.
Our study found reduced miR302-367 expression in ECs when cocultured with LLC1 cells. It was reported that in embryonic stem cells, pluripotent transcription factors Oct4 and Sox2 bind to a conserved promoter region of miR-302 and transactivate miR-302 and maintain embryonic stem cell pluripotency. 28 A recent study showed that Wnt/β-catenin can regulate miR302 expression by binding to its promoter, and Wnt/β-catenin was activated in tumor vessels, and enforced endothelial Wnt/β-catenin blocked tumor angiogenesis 29, 30 ; thus, future study will explore whether Wnt/β-Catenin or other signals can regulate miR302-367 expression that control angiogenesis.
Lin et al 31 found that miR302-367 reprogrammed somatic cells to pluripotent cells; they also reported that miR-302 suppressed both cyclin pathways to block >70% of the G1-S cell cycle transition, and concurrent silenced BMI-1, a cancer stem cell marker, thus inhibited the tumorgenecity of human pluripotent stem cells. 19 Many other studies reported that miR-302 inhibited tumorigenicity through suppression of cell cycle progression and Akt pathway. 13, 14 Therefore, miR-302-367 can reprogram somatic cells to pluripotent cells, but also inhibit the tumorgenecity of pluripotent stem cells. Our study used a genetic model and found that EC-specific miR302-367 and targeted miR302-367 delivery specifically to ECs restricted angiogenesis and stabilized blood vessel and retarded the xenograft tumor growth.
We identified that Erk1/2 was a direct target of miR302-367 via RNA high-throughput sequence followed by qPCR and luciferase assay. Individual miR302a/b/c/d and miR367 mimics were found to repress 3′-UTR of Erk1/2 as miR302-367 cluster vector. The mimics can also repress 3′-UTR of ccnd1, cdc42, and rac1, which are involved in regulation of cell migration and proliferation (data not shown). Taken together, these results indicated that miR302-367 cluster and individual miR302a/b/c/d and miR367 mimics exerted antiangiogenic effects by targeting multiple genes, in which Erk1/2 was the essential target of mir302-367, and the antiangiogenic effect of mir302-367 was dependent on Erk1/2-Klf2-S1r1 pathway.
ECs in the adult mammal are among the least proliferative cell types, and these quiescent cells can rapidly reverse to proliferative cells during pathological neovascularization, particularly during tumorigenesis, and inhibition of angiogenesis is a promising strategy for cancer therapy. 1 MicroRNAs, a new class of small RNA molecules, have emerged as key regulators of cellular processes including angiogenesis by targeting multiple regulating pathways, [5] [6] [7] which provide more effective synergy and might prevent development of evasive resistance as anti-Vegfr-2 antibody in cancer therapy.
Recent studies have provided detailed information on balancing the opposing functions of Vegf and S1pr1 signals in angiogenesis, of which Vegf mediates angiogenic sprouting initiation, elongation, and branching, 32 while S1pr1 terminates sprouting angiogenesis through inhibition of Vegf-induced phosphorylation of Vegf2, Erk1/2, and Akt and improves vascular stability EC autonomously. 27, 33 This study showed elevated miR302-367 expression in EC reduced retinal and embryonic hindbrain sprout angiogenesis, the cells had reduced Erk1/2 but increased Klf2, S1pr1, and VE-cadherin expression. Erk1/2 activated by Vegf could reduce the enhanced expression of Klf2, S1pr1, and VEcadherin, and a specific inhibitor SCH772984 reverse these effects, confirming that Erk1/2-Klf2-S1pr1-VE-cadherin pathway in ECs on elevated expression of miR302-367 contributes to the reduction of sprout angiogenesis. ECs on elevated expression of miR302-367 exhibited no significant expression change of cleaved caspase-3, suggesting that the reduced sprout angiogenesis was not because of cell apoptosis.
Both S1pr1 and Klf2 are critical for EC mechanotransduction, which inhibit Vegf-mediated angiogenesis and vascular permeability. 26, 27 Similar embryo lethality around E12.5 was found in S1pr1 or Klf2 knockout mice as a result of severe bleeding throughout the bodies because of defect in maturation of blood vessels, 34, 35 suggesting that they both are important in vasculature formation. Klf2 was reported to be a crucial transcription factor to enhance S1pr1 expression in T cells. 36 Our results found that ≈3-fold increase of Klf2 expression in HUVECs enhanced both RNA and protein expression of S1pr1, indicating that Klf2 could increase S1pr1 expression in ECs.
Key insights into the effect of upregulation of S1pr1 on elevated miR302-367 expression in ECs on the restriction of sprout angiogenesis and improvement of vascular stability of retinal vasculature were obtained by rescue study of pharmacological blockade with selective S1pr1 antagonist or genetic deletion of EC-specific S1pr1 in S1pr1 fl/ fl :miR302-367 ECTg mice. It has been shown that S1P/S1pr1 signaling restricted angiogenic sprouting and stabilized junctional VE-cadherin, which played an important role in the maintenance of vascular integrity and the regulation of vascular permeability. 27 Here, we showed that elevation of miR302-367 expression in ECs upregulated S1pr1, leading to the increased VE-cadherin at endothelial junctions, which restricted retina angiogenesis and improved vascular stability. Either pharmacological or genetic deletion of S1pr1 reversed the upregulation of total and junctional VEcadherin, hence boosted retina angiogenesis and weakened the vascular stability.
In conclusion, this study found that miR302-367 regulation of an Erk1/2-Klf2-S1pr1 pathway in the endothelium could restrict both development and tumor angiogenesis, improve vascular stability, and potently retard tumor growth, therefore offering a novel strategy to improve anticancer therapy.
